|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||10.40 - 10.65|
|52 Week Range||6.55 - 11.25|
|Beta (5Y Monthly)||1.19|
|PE Ratio (TTM)||16.29|
|Forward Dividend & Yield||0.62 (6.02%)|
|Ex-Dividend Date||May 24, 2021|
|1y Target Est||N/A|
MILAN (Reuters) -Generali's appointments committee recommended that the board finalise a slate of nominees for its renewal keeping Philippe Donnet as CEO for another term, three sources close to the situation told Reuters on Friday. Generali's board meets on Monday to discuss whether to submit its own slate of nominees, including Donnet, ahead of a general meeting next spring to name new directors. Donnet has come under pressure from some major shareholders who are critical of his strategy.
Generali's biggest investor Mediobanca said on Thursday it had borrowed shares in Italy's top insurer to secure 17.2% of voting rights, upping the ante in a shareholder tussle over the choice of the next chief executive. With its 12.9% stake Mediobanca is the single largest shareholder in Generali, followed by Italian billionaires Francesco Gaetano Caltagirone and Leonardo Del Vecchio. The two tycoons have struck a pact to consult over decisions concerning Generali and people with knowledge of the matter have said they will back a different CEO candidate if Generali's board proposes appointing current boss Philippe Donnet for another mandate.
Italian asset manager Banca Generali said there had been no new writedowns on bonds linked to the healthcare system, after a report in the Financial Times on Thursday highlighted recent provisions. The Financial Times reported that Banca Generali had written down the value of almost 500 million euros of such bonds. A spokesperson for Banca Generali referred to a July 27 statement by the company which had flagged 80 million euros in provisions on investments on healthcare receivables.